Prognostic and Predictive Impact of HER2 Alterations in mCRC Treated with Chemotherapy–Bevacizumab vs Anti-EGFR Therapy
The prognostic and predictive impact of HER2 alterations (amplification or mutation) in metastatic colorectal cancer (mCRC) was evaluated through a pooled analysis of eight major randomized clinical trials, involving 1,604 patients with RAS/BRAF wild-type, microsatellite-stable tumors. The key findings are as follows:
Prognostic Impact:
Prevalence of HER2 Alterations: Approximately 5% of patients had HER2 amplification or overexpression, while about 2% harbored activating HER2 mutations.
Worse Survival Outcomes: Patients with HER2-positive tumors had significantly worse outcomes compared to HER2-negative patients:
- Progression-Free Survival (PFS): HER2-positive patients had a shorter PFS (9.8 months) compared to HER2-negative patients (12.2 months).
- Overall Survival (OS): HER2-positive patients had a reduced OS (28.0 months) compared to HER2-negative patients (34.9 months).
- HER2 Positivity as a Negative Prognostic Factor: These survival differences persisted even after adjusting for covariates, confirming that HER2 positivity is an independent negative prognostic factor in mCRC.
Predictive Impact:
Objective Response Rates (ORR): The ORR was similar between HER2-positive and HER2-negative groups, indicating that HER2 status does not influence the initial response to treatment.
Efficacy of Biologic Therapies:
- No significant interaction was observed between HER2 status and the efficacy of biologic therapies.
- Patients with HER2 alterations derived comparable benefit from chemotherapy combined with either bevacizumab (anti-VEGF) or anti-EGFR agents.
- HER2-Mutant Tumors: These tumors also demonstrated worse overall survival but did not show a differential response to biologic therapies.
Conclusion:
HER2 amplification or mutation is associated with poorer prognosis in mCRC but does not alter the efficacy of standard targeted therapies, such as chemotherapy with bevacizumab or anti-EGFR agents. These findings highlight the need for HER2-directed treatment strategies to improve outcomes in this subset of patients.
